The Honest Answer First
There is no official price list for patents. Every rate you'll see published — including the ones below — comes from surveys of licensing deals, court damages awards, and databases of agreements that companies were forced to disclose. Real licenses are private, and identical-looking patents can license for wildly different numbers depending on who needs whom more. That said, the survey data is remarkably consistent about the ranges each industry pays, and knowing your range is the difference between negotiating and guessing.
Commonly Cited Ranges by Industry
Figures below reflect running royalties as a percentage of net sales, drawn from the ranges most often cited in licensing surveys and published deal databases:
| Industry | Typical range | Notes |
|---|---|---|
| Pharmaceuticals | 5–10% | Approved, marketed drugs; deals on late-stage compounds can exceed this, early-stage ones sit lower with milestone payments doing the heavy lifting |
| Biotechnology | 2–8% | Highly stage-dependent; upfront fees and milestones often matter more than the rate |
| Medical devices | 3–5% | One of the most stable, frequently licensed categories |
| Software | 5–10% | Wide variance; hybrid structures common |
| Consumer electronics | 2–5% | Royalty stacking pressure keeps individual rates down |
| Semiconductors | 1–3% | Thin margins, dense patent thickets |
| Automotive | 1–3% | High volumes, low rates |
| Chemicals & materials | 2–4% | Process patents often priced per unit instead |
| Consumer products | 2–5% | Overlaps with brand licensing economics |
Notice the pattern: rates track margins. Pharma can pay 10% because a patented drug's gross margin can absorb it. A carmaker selling on 8% margins cannot hand a third of that to one patent holder — especially when a modern vehicle practices thousands of patents at once.
The Rise and Fall of the 25% Rule
For decades, licensing negotiations leaned on a rule of thumb: the patent owner gets roughly 25% of the licensee's expected operating profit from the patented product, which — at typical margins — back-calculates into the single-digit sales percentages above. It was tidy, it was everywhere, and in 2011 the Federal Circuit killed it as courtroom evidence in Uniloc v. Microsoft, calling it a "fundamentally flawed" abstraction untethered from the actual patent and the actual parties.
The rule still floats around as a private sanity check, but damages experts now have to build rates from comparable licenses and the Georgia-Pacific factors — a fifteen-item list courts use that boils down to: what would these two parties have agreed to in a hypothetical negotiation, given the patent's strength, the available alternatives, exclusivity, and the profit the invention actually drives?
Rate × Base: The Half Everyone Forgets
Negotiators obsess over the percentage and then give away the game on what it's a percentage of. A 2% royalty on a $900 smartphone is $18; a 2% royalty on the $4 component that actually embodies the invention is eight cents. US damages law increasingly pushes toward the smallest salable unit that practices the patent, precisely to stop small inventions from taxing entire products. In private deals the base is whatever you agree — which is why the definition of "net sales" (returns? freight? bundled services?) deserves as much lawyer time as the rate itself.
What Moves a Rate Up or Down
Up: exclusivity (commonly a 2–3× multiplier), a patent that's survived litigation or an IPR challenge, no viable design-around, the licensee already infringing, strong remaining patent life.
Down: non-exclusive grants, easy alternatives, a crowded field where the licensee must stack many royalties, weak or untested claims, a license bundled with know-how the licensor wants to move anyway.
One more quiet driver: who goes first. A licensor who has published rates or granted prior licenses is anchored to them — a fact that cuts both ways in negotiation and in court.
Patents vs. Trademarks: Different Logic
If you've read our trademark royalty benchmarks, the numbers look similar — mostly single digits of net sales — but the reasoning differs. A trademark royalty prices consumer recognition, so it scales with brand fame. A patent royalty prices exclusion: what it costs the licensee to not have this technology, versus their next-best alternative. That's why an obscure patent with no design-around can out-earn a famous one with ten substitutes, and why patent rates collapse the day the patent expires — while a strong brand can license forever.
FAQ
What is a typical patent royalty rate?
Most running royalties fall between 1% and 10% of net sales. Pharmaceutical and medical device patents sit at the high end (roughly 3–10%), while automotive, semiconductor, and other thin-margin, patent-dense industries typically pay 1–3%.
Is the 25% rule still used?
Not in US courtrooms — the Federal Circuit rejected it as damages evidence in Uniloc v. Microsoft (2011). Some negotiators still use profit-split logic privately, but comparable licenses are the accepted foundation for pricing.
Are patent royalties higher than trademark royalties?
The ranges overlap heavily — low single digits of net sales in most industries for both. The drivers differ: patent rates track the cost of the licensee's next-best alternative, while trademark rates track brand strength and consumer pull.